Biopolitics for the 21st Century
By Marcy Darnovsky,
2020 Science
| 12. 14. 2009
Much appreciation is due to Andrew for his courage in soliciting "alternative perspectives" on technology innovation and life in the 21st century. I can't help but observe that his nervousness about doing so is one small sign that something is amiss in what he calls "the interface between emerging technologies and society."
One challenge we face in mending that interface is a tendency toward over-enthusiasm about prospective technologies. Another is the entanglement of technology innovation and commercial dynamics. Neither of these is brand new.
Back in the last century, the 1933 Chicago World's Fair took "technological innovation" as its theme and "A Century of Progress" as its formal name. Its official motto was "Science Finds, Industry Applies, Man Conforms."
The slogan shamelessly depicts "science" and "industry" as dictator - or at least drill sergeant - of humanity. It anoints industrial science as a rightful decision-maker about human ends, and an inevitable purveyor of societal uplift.
Today the 1933 World's Fair slogan seems altogether crass. But have we earned our cringe? We'd like to think that we're more realistic about science...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...